Several common medication categories can worsen breathing in people with COPD, either by suppressing respiratory drive, tightening airways, or making it harder to clear mucus. Some are prescription drugs you might take for an unrelated condition; others are over-the-counter products you’d pick up without a second thought. Knowing which ones carry risk helps you have smarter conversations with your doctor and pharmacist.
Non-Selective Beta-Blockers
Beta-blockers are widely prescribed for high blood pressure, heart failure, and irregular heart rhythms. They work by slowing the heart and reducing its workload, but the non-selective versions (propranolol and nadolol are the most recognized) also block receptors in the airways. Those receptors normally help keep bronchial muscles relaxed. When they’re blocked, the airways can tighten, increasing airway hyperresponsiveness, a problem directly linked to higher mortality in COPD.
Cardioselective beta-blockers like metoprolol and atenolol were long considered safer because they primarily target the heart. However, the picture is more complicated than it appears. Research published in the American Journal of Respiratory and Critical Care Medicine found that metoprolol’s effect on airway hyperresponsiveness was essentially the same as propranolol’s in COPD patients, suggesting that even “selective” beta-blockers still interfere with airway receptors to some degree. A large trial called BLOCK-COPD, which tested metoprolol specifically in people with COPD, was stopped early after finding a higher rate of exacerbations requiring hospitalization in the metoprolol group.
That said, beta-blockers aren’t automatically off the table. A separate cohort study found that beta-blocker prescriptions at hospital discharge were not associated with worse outcomes in COPD patients who had just had a heart attack. The takeaway: if you genuinely need a beta-blocker for a serious cardiac condition, the benefit may outweigh the lung risk, but it requires careful monitoring rather than a casual prescription.
Opioid Pain Medications
Opioids suppress the brain’s respiratory drive, slowing both breathing rate and depth. For someone with healthy lungs, this effect is usually manageable at normal doses. For someone with COPD, whose lungs already struggle to exchange oxygen and carbon dioxide efficiently, even a standard dose can tip the balance toward dangerously shallow breathing.
The risk escalates sharply when opioids are combined with benzodiazepines. Both drug classes cause sedation and suppress breathing through separate mechanisms, and together their respiratory effects compound. A prospective cohort study in people with COPD found that coprescribing opioids and benzodiazepines increases the risk of life-threatening overdose, with the impaired lung function of COPD making fatal respiratory depression more likely than it would be in the general population.
Benzodiazepines and Sedatives
Benzodiazepines like diazepam, lorazepam, and alprazolam are prescribed for anxiety, insomnia, and muscle spasms. They depress central respiratory drive and blunt the brain’s ability to sense rising carbon dioxide levels. In COPD, the body often already retains more carbon dioxide than normal. Adding a drug that dulls the brain’s alarm system for high CO₂ can lead to a dangerous buildup, a condition called hypercapnia, which in severe cases causes confusion, loss of consciousness, or respiratory failure.
This doesn’t mean anxiety and insomnia go untreated. But the choice of medication matters enormously when your lungs are already compromised. If you’re currently taking a benzodiazepine and have COPD, it’s worth raising the question with your prescriber rather than stopping abruptly, since sudden withdrawal carries its own serious risks.
First-Generation Antihistamines
Older antihistamines like diphenhydramine (the active ingredient in Benadryl and many nighttime cold formulas) pose a double problem for COPD. Beyond blocking histamine, these drugs are fairly potent at blocking a second receptor type called muscarinic receptors. That antimuscarinic action dries out the mucus membranes lining your airways and thickens the mucus that remains. For someone with COPD, who already produces excess mucus and depends on being able to cough it up, thicker, stickier secretions can plug smaller airways and trigger flare-ups.
First-generation antihistamines also cause drowsiness, which layers a mild sedative effect on top of the mucus problem. Newer antihistamines like cetirizine, loratadine, and fexofenadine don’t cross into the brain as easily and have far less antimuscarinic activity, making them a better choice for allergy relief when you have COPD.
Cough Suppressants
It’s tempting to reach for a cough suppressant when COPD keeps you coughing, but suppressing that cough can backfire. Coughing is one of the main ways your lungs clear mucus from the airways. In COPD, mucus production is often elevated, and the tiny hair-like structures that normally sweep mucus upward are damaged. Cough is the backup system. Medications containing dextromethorphan or codeine (which is also an opioid) reduce the cough reflex and can allow secretions to pool in the lungs, raising the risk of infection and worsening airflow obstruction.
Certain NSAIDs
Standard anti-inflammatory painkillers like aspirin, ibuprofen, naproxen, and ketorolac are generally fine for most people with COPD alone. The concern applies to a specific subset of patients who also have asthma or a condition called aspirin-exacerbated respiratory disease (AERD). AERD involves asthma, chronic sinus inflammation with nasal polyps, and respiratory reactions triggered by any drug that inhibits the COX-1 enzyme.
In people with this sensitivity, symptoms typically develop within 30 minutes to 3 hours after taking the medication and can include a significant drop in lung function. In oral aspirin challenge studies, 39% of sensitive patients experienced a greater than 20% fall in their breathing capacity. Because COPD and asthma can overlap, particularly in long-term smokers who also have allergic airway disease, this sensitivity sometimes goes unrecognized until a reaction occurs. If you’ve ever noticed worsening breathing after taking ibuprofen or aspirin, that history is important to share with your care team.
Long-Term Oral Corticosteroids
Short courses of oral steroids like prednisone are a standard rescue treatment for COPD flare-ups. The problem is long-term or frequently repeated use. The 2024 GOLD guidelines state plainly that long-term oral corticosteroids have numerous side effects with no evidence of sustained benefit in COPD.
A large UK study quantified how quickly the damage accumulates. Compared to patients with minimal steroid exposure, those who reached a cumulative dose equivalent to roughly four standard rescue courses had a 45% higher risk of osteoporosis. Patients who accumulated higher doses saw that risk climb to 89%. Beyond bone loss, repeated courses contribute to muscle weakness (a particular problem since respiratory muscles are already taxed in COPD), elevated blood sugar, weight gain, and increased susceptibility to infections. Every rescue course should prompt a clinical review to consider whether additional controller therapies could reduce the need for steroids going forward.
Oral Anticholinergics
Many COPD patients use inhaled anticholinergic bronchodilators like tiotropium or ipratropium to keep airways open. These inhaled forms are designed as charged molecules that stay in the lungs and are barely absorbed into the bloodstream, which is why they work locally without causing widespread side effects.
Oral anticholinergics are a different story. Drugs with anticholinergic effects show up in unexpected places: older antidepressants, bladder medications for overactive bladder, certain antipsychotics, and anti-nausea drugs. Taken by mouth, these medications are absorbed systemically and can cause dry mouth, urinary retention, constipation, blurred vision, and confusion, especially in older adults. They also dry airway secretions in the same way first-generation antihistamines do. If you’re already on an inhaled anticholinergic for COPD, stacking oral anticholinergic drugs on top increases side effects without adding lung benefit.
Theophylline and Related Methylxanthines
Theophylline was once a mainstay of COPD treatment, but the 2024 GOLD guidelines no longer recommend methylxanthines due to their side effect profile relative to their modest benefit. The therapeutic window is narrow: the dose that helps is close to the dose that causes problems. Common adverse effects include gastrointestinal upset, insomnia, rapid heart rate, and potentially dangerous heart rhythm disturbances. Drug interactions are also a concern, since many common medications and even dietary changes can push theophylline levels into a toxic range.